Multiresponse Designs and Surrogate Endpoints in Clinical Trials
نویسنده
چکیده
Incorporating plausible surrogate variates, a general class of incomplete multiresponse designs for clinical trials is considered. In this context, the basic differences between the conventional linear models and survival analysis models are discussed thoroughly. Along with some parametric and semi-parametric procedures, suitable nonparametric ones are considered, and the related asymptotic theory is presented. AMS Subject Classification: 62PIO, 62KIO, 62G99
منابع مشابه
From Clinical Trials to Clinical Epidemiology
Outcomes research seeks to identify effective evidence-based methods of providing the best medical care. While randomized clinical trials (RCT) usually provide the clearest answers, they are often not done or not practicable. More than a decade after the introduction of calcium channel blockers and angiotensin converting enzyme (ACE) inhibitors, clinical trial data about their effect on major d...
متن کاملTwo Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
BACKGROUND Surrogate endpoint trials test strategies more efficiently but are accompanied by uncertainty about the relationship between changes in surrogate markers and clinical outcomes. METHODS AND RESULTS We identified cardiovascular trials with primary surrogate endpoints published in the New England Journal of Medicine, Lancet, and JAMA: Journal of the American Medical Association from 1...
متن کاملStatistical Issues in Evaluation of Surrogate Endpoints
Among the most important issues in the design of a clinical trial is the selection of the primary endpoint. Fleming et al. (1998) provided two criteria to govern its selection: the endpoint should be (i) sensitive to treatment effects, and (ii) clinically relevant. Endpoints that directly reflect how a patient feels, functions, or survives have clear clinical relevance; we refer to these as tru...
متن کاملBiomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma
With the recent progress in imaging technologies for assessment of structural damage in glaucoma, a debate has emerged on whether these measurements can be used as valid surrogate endpoints in clinical trials evaluating new therapies for the disease. A discussion of surrogates should be grounded on knowledge acquired from their use in other areas of medicine as well as regulatory requirements. ...
متن کاملHard, harder, hardest: principal stratification, statistical identifiability, and the inherent difficulty of finding surrogate endpoints
In many areas of clinical investigation there is great interest in identifying and validating surrogate endpoints, biomarkers that can be measured a relatively short time after a treatment has been administered and that can reliably predict the effect of treatment on the clinical outcome of interest. However, despite dramatic advances in the ability to measure biomarkers, the recent history of ...
متن کامل